Trials / Terminated
TerminatedNCT00739960
Safety Study of Abatacept to Treat Refractory Sarcoidosis
Sarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive Sarcoidosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abatacept | 10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-08-22
- Last updated
- 2020-03-23
- Results posted
- 2020-03-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00739960. Inclusion in this directory is not an endorsement.